Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H13NO7P2 |
Molecular Weight | 249.0962 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
InChI
InChIKey=OGSPWJRAVKPPFI-UHFFFAOYSA-N
InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)
Alendronic acid is a bisphosphonate drug used for osteoporosis, osteogenesis imperfecta, and several other bone diseases. It is marketed alone as well as in combination with vitamin D. Alendronate inhibits osteoclast-mediated bone-resorption. Like all bisphosphonates, it is chemically related to inorganic pyrophosphate, the endogenous regulator of bone turnover. But while pyrophosphate inhibits both osteoclastic bone resorption and the mineralization of the bone newly formed by osteoblasts, alendronate specifically inhibits bone resorption without any effect on mineralization at pharmacologically achievable doses. Its inhibition of bone-resorption is dose-dependent and approximately 1,000 times stronger than the equimolar effect of the first bisphosphonate drug, etidronate. Under therapy, normal bone tissue develops, and alendronate is deposited in the bone-matrix in a pharmacologically inactive form. For optimal action, enough calcium and vitamin D are needed in the body in order to promote normal bone development. Hypocalcemia should, therefore, be corrected before starting therapy. Treatment of post-menopausal women and people with osteogenesis imperfecta over the age of 22 with alendronic acid has demonstrated normalization of the rate of bone turnover, significant increase in BMD (bone mineral density) of the spine, hip, wrist and total body, and significant reductions in the risk of vertebral (spine) fractures, wrist fractures, hip fractures, and all non-vertebral fractures. In the Fracture Intervention Trial, the women with the highest risk of fracture (by virtue of pre-existing vertebral fractures) were treated with Fosamax 5 mg/day for two years followed by 10 mg/day for the third year. This resulted in approximately 50% reductions in fractures of the spine, hip, and wrist compared with the control group taking placebos. Both groups also took calcium and vitamin D.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1782 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18327899 |
260.0 nM [IC50] | ||
Target ID: CHEMBL4769 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18800762 |
436.52 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FOSAMAX Approved UseINDICATIONS AND USAGE. FOSAMAX is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women (1.1, 1.2) Treatment to increase bone mass in men with osteoporosis (1.3) Treatment of glucocorticoid-induced osteoporosis (1.4) Treatment of Paget's disease of bone (1.5) Important limitations of use: The optimal duration of use has not been determined. The need for continued therapy should be re-evaluated on a periodic basis. (1.6) Launch Date9.3381119E11 |
|||
Primary | FOSAMAX Approved UseINDICATIONS AND USAGE. FOSAMAX is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women (1.1, 1.2) Treatment to increase bone mass in men with osteoporosis (1.3) Treatment of glucocorticoid-induced osteoporosis (1.4) Treatment of Paget's disease of bone (1.5) Important limitations of use: The optimal duration of use has not been determined. The need for continued therapy should be re-evaluated on a periodic basis. (1.6) Launch Date9.3381119E11 |
|||
Primary | FOSAMAX Approved UseINDICATIONS AND USAGE. FOSAMAX is a bisphosphonate indicated for: Treatment and prevention of osteoporosis in postmenopausal women (1.1, 1.2) Treatment to increase bone mass in men with osteoporosis (1.3) Treatment of glucocorticoid-induced osteoporosis (1.4) Treatment of Paget's disease of bone (1.5) Important limitations of use: The optimal duration of use has not been determined. The need for continued therapy should be re-evaluated on a periodic basis. (1.6) Launch Date9.3381119E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
56.62 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28744102 |
70 mg single, oral dose: 70 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALENDRONATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
155.53 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28744102 |
70 mg single, oral dose: 70 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALENDRONATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.73 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28744102 |
70 mg single, oral dose: 70 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALENDRONATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Long-term therapy for postmenopausal osteoporosis: stronger bones but weaker arteries. | 1999 Jul 27 |
|
Ocular inflammation associated with alendronate therapy. | 1999 Jun |
|
[Pain relief with alendronate therapy in a breast cancer patient with bone metastasis]. | 2000 Apr |
|
Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression. | 2000 Aug |
|
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. | 2000 Jan 1 |
|
A peptide prodrug approach for improving bisphosphonate oral absorption. | 2000 Oct 5 |
|
Initiation of osteoporosis treatment after bone mineral density testing. | 2001 |
|
Alendronate: an update of its use in osteoporosis. | 2001 |
|
A slow outward current and a hypoosmolality induced anion conductance in embryonic chicken osteoclasts. | 2001 |
|
Hyposecretion of the adrenal androgen dehydroepiandrosterone sulfate and its relation to clinical variables in inflammatory arthritis. | 2001 |
|
Fractures after long-term alendronate therapy. | 2001 Apr |
|
Risk of ulcer soars with combination of arthritis drugs. | 2001 Apr |
|
Analgesic effect of bisphosphonates in mice. | 2001 Apr |
|
Effect of alendronate on bone mineral density in male idiopathic osteoporosis. | 2001 Aug |
|
Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. | 2001 Feb |
|
Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. | 2001 Feb |
|
Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects. | 2001 Feb |
|
[Diagnosis of primary Sjogren's syndrome]. | 2001 Feb 20 |
|
Prevention of bone loss in kidney graft recipients. | 2001 Feb-Mar |
|
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. | 2001 Jan |
|
Once-a-week alendronate for postmenopausal osteoporosis is as effective as once-daily dosing. | 2001 Jan |
|
Phosphate ions mediate chondrocyte apoptosis through a plasma membrane transporter mechanism. | 2001 Jan |
|
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures]. | 2001 Jul 14 |
|
New possibilities for diagnosis and treatment of osteoporosis. | 2001 Jul-Aug |
|
Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. | 2001 Jun |
|
Osteoporosis. | 2001 Jun |
|
Osteoporosis in men. | 2001 Jun 15 |
|
Estimating probability of non-response to treatment using mixture distributions. | 2001 Jun 30 |
|
Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. | 2001 Mar |
|
Prevention of corticosteroid induced osteoporosis in inpatients recently discharged from a tertiary teaching hospital. | 2001 Mar |
|
Evidence-based medicine: putting theory into practice. | 2001 Mar |
|
Managing menopause after breast cancer: balancing risks and benefits. | 2001 Mar |
|
Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly. | 2001 Mar |
|
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. | 2001 Mar |
|
Labelling of Re-ABP with 188Re for bone pain palliation. | 2001 Mar |
|
Once-a-week alendronate (Fosamax). | 2001 Mar 19 |
|
[Esophagitis associated with use of alendronate in 5 postmenopausic patients]. | 2001 May |
|
Why do older women discontinue hormone replacement therapy? | 2001 May |
|
Bones and Crohn's: should we treat Crohn's disease patients with alendronate? | 2001 May |
|
Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. | 2001 May |
|
Absolute vs. relative numbers in evaluating drug therapy. | 2001 May 15 |
|
Prevention of bone loss and fracture after lung transplantation: a pilot study. | 2001 Oct 15 |
|
Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone. | 2001 Sep |
|
Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission. | 2001 Sep |
|
Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis. | 2001 Spring |
|
What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting? | 2001 Summer |
Patents
Sample Use Guides
Treatment of Osteoporosis in Postmenopausal Women: one 70 mg tablet once weekly
Prevention of Osteoporosis in Postmenopausal Women: one 35 mg tablet once weekly
Treatment to Increase Bone Mass in Men with Osteoporosis: one 70 mg tablet once weekly
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25339667
IGROV-1 ovarian carcinoma cells were stained with PKH26 (Sigma-Aldrich) according to the manufacturer’s instructions and then incubated with the indicated AA (Alendronic acid ) for 24 h. After washing, 1 3 106 target cells and 1 3 106 ex vivo expanded gd T cells were cocultured at 37°C/5% CO2 for 4 h and then stained with Annexin VFITC (BD Pharmingen)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
166603
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
WHO-ATC |
M05BB05
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
NDF-RT |
N0000175579
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
LIVERTOX |
22
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
WHO-VATC |
QM05BB05
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
WHO-VATC |
QM05BB06
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
NDF-RT |
N0000007707
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
WHO-ATC |
M05BB06
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
NCI_THESAURUS |
C443
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
WHO-ATC |
M05BB03
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
NCI_THESAURUS |
C67439
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
WHO-VATC |
QM05BB03
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
WHO-ATC |
M05BA04
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
||
|
WHO-VATC |
QM05BA04
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00630
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
X1J18R4W8P
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
112
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
66376-36-1
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
C61625
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
3141
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
Alendronate
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
6462
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
M1493
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | Merck Index | ||
|
D019386
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
7990
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
236083
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
CHEMBL870
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
ALENDRONIC ACID
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
46041
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
ALTERNATIVE | |||
|
2088
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
66376-36-1
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY | |||
|
SUB05307MIG
Created by
admin on Sat Jun 26 06:43:48 UTC 2021 , Edited by admin on Sat Jun 26 06:43:48 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)